Eintrag weiter verarbeiten
Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine
Gespeichert in:
| Zeitschriftentitel: | Antimicrobial Agents and Chemotherapy |
|---|---|
| Personen und Körperschaften: | , , , , , |
| In: | Antimicrobial Agents and Chemotherapy, 61, 2017, 5 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Society for Microbiology
|
| Schlagwörter: |
| author_facet |
Permala, Jesmin Tarning, Joel Nosten, François White, Nicholas J. Karlsson, Mats O. Bergstrand, Martin Permala, Jesmin Tarning, Joel Nosten, François White, Nicholas J. Karlsson, Mats O. Bergstrand, Martin |
|---|---|
| author |
Permala, Jesmin Tarning, Joel Nosten, François White, Nicholas J. Karlsson, Mats O. Bergstrand, Martin |
| spellingShingle |
Permala, Jesmin Tarning, Joel Nosten, François White, Nicholas J. Karlsson, Mats O. Bergstrand, Martin Antimicrobial Agents and Chemotherapy Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine Infectious Diseases Pharmacology (medical) Pharmacology |
| author_sort |
permala, jesmin |
| spelling |
Permala, Jesmin Tarning, Joel Nosten, François White, Nicholas J. Karlsson, Mats O. Bergstrand, Martin 0066-4804 1098-6596 American Society for Microbiology Infectious Diseases Pharmacology (medical) Pharmacology http://dx.doi.org/10.1128/aac.02491-16 <jats:title>ABSTRACT</jats:title> <jats:p>Intermittent preventive treatment (IPT) is used to reduce malaria morbidity and mortality, especially in vulnerable groups such as children and pregnant women. IPT with the fixed dose combination of piperaquine (PQ) and dihydroartemisinin (DHA) is being evaluated as a potential mass treatment to control and eliminate artemisinin-resistant falciparum malaria. This study explored alternative DHA-PQ adult dosing regimens compared to the monthly adult dosing regimen currently being studied in clinical trials. A time-to-event model describing the concentration-effect relationship of preventive DHA-PQ administration was used to explore the potential clinical efficacy of once-weekly adult dosing regimens. Loading dose strategies were evaluated and the advantage of weekly dosing regimen was tested against different degrees of adherence. Assuming perfect adherence, three tablets weekly dosing regimen scenarios maintained malaria incidence of 0.2 to 0.3% per year compared to 2.1 to 2.6% for all monthly dosing regimen scenarios and 52% for the placebo. The three tablets weekly dosing regimen was also more forgiving (i.e., less sensitive to poor adherence), resulting in a predicted ∼4% malaria incidence per year compared to ∼8% for dosing regimen of two tablets weekly and ∼10% for monthly regimens (assuming 60% adherence and 35% interindividual variability). These results suggest that weekly dosing of DHA-PQ for malaria chemoprevention would improve treatment outcomes compared to monthly administration by lowering the incidence of malaria infections, reducing safety concerns about high PQ peak plasma concentrations and being more forgiving. In addition, weekly dosing is expected to reduce the selection pressure for PQ resistance.</jats:p> Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine Antimicrobial Agents and Chemotherapy |
| doi_str_mv |
10.1128/aac.02491-16 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin Chemie und Pharmazie |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTEyOC9hYWMuMDI0OTEtMTY |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTEyOC9hYWMuMDI0OTEtMTY |
| institution |
DE-D275 DE-Bn3 DE-Brt1 DE-Zwi2 DE-D161 DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 |
| imprint |
American Society for Microbiology, 2017 |
| imprint_str_mv |
American Society for Microbiology, 2017 |
| issn |
0066-4804 1098-6596 |
| issn_str_mv |
0066-4804 1098-6596 |
| language |
English |
| mega_collection |
American Society for Microbiology (CrossRef) |
| match_str |
permala2017predictionofimprovedantimalarialchemopreventionwithweeklydosingofdihydroartemisininpiperaquine |
| publishDateSort |
2017 |
| publisher |
American Society for Microbiology |
| recordtype |
ai |
| record_format |
ai |
| series |
Antimicrobial Agents and Chemotherapy |
| source_id |
49 |
| title |
Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine |
| title_unstemmed |
Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine |
| title_full |
Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine |
| title_fullStr |
Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine |
| title_full_unstemmed |
Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine |
| title_short |
Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine |
| title_sort |
prediction of improved antimalarial chemoprevention with weekly dosing of dihydroartemisinin-piperaquine |
| topic |
Infectious Diseases Pharmacology (medical) Pharmacology |
| url |
http://dx.doi.org/10.1128/aac.02491-16 |
| publishDate |
2017 |
| physical |
|
| description |
<jats:title>ABSTRACT</jats:title>
<jats:p>Intermittent preventive treatment (IPT) is used to reduce malaria morbidity and mortality, especially in vulnerable groups such as children and pregnant women. IPT with the fixed dose combination of piperaquine (PQ) and dihydroartemisinin (DHA) is being evaluated as a potential mass treatment to control and eliminate artemisinin-resistant falciparum malaria. This study explored alternative DHA-PQ adult dosing regimens compared to the monthly adult dosing regimen currently being studied in clinical trials. A time-to-event model describing the concentration-effect relationship of preventive DHA-PQ administration was used to explore the potential clinical efficacy of once-weekly adult dosing regimens. Loading dose strategies were evaluated and the advantage of weekly dosing regimen was tested against different degrees of adherence. Assuming perfect adherence, three tablets weekly dosing regimen scenarios maintained malaria incidence of 0.2 to 0.3% per year compared to 2.1 to 2.6% for all monthly dosing regimen scenarios and 52% for the placebo. The three tablets weekly dosing regimen was also more forgiving (i.e., less sensitive to poor adherence), resulting in a predicted ∼4% malaria incidence per year compared to ∼8% for dosing regimen of two tablets weekly and ∼10% for monthly regimens (assuming 60% adherence and 35% interindividual variability). These results suggest that weekly dosing of DHA-PQ for malaria chemoprevention would improve treatment outcomes compared to monthly administration by lowering the incidence of malaria infections, reducing safety concerns about high PQ peak plasma concentrations and being more forgiving. In addition, weekly dosing is expected to reduce the selection pressure for PQ resistance.</jats:p> |
| container_issue |
5 |
| container_start_page |
0 |
| container_title |
Antimicrobial Agents and Chemotherapy |
| container_volume |
61 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792347299773415431 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T17:51:43.56Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Prediction+of+Improved+Antimalarial+Chemoprevention+with+Weekly+Dosing+of+Dihydroartemisinin-Piperaquine&rft.date=2017-05-01&genre=article&issn=1098-6596&volume=61&issue=5&jtitle=Antimicrobial+Agents+and+Chemotherapy&atitle=Prediction+of+Improved+Antimalarial+Chemoprevention+with+Weekly+Dosing+of+Dihydroartemisinin-Piperaquine&aulast=Bergstrand&aufirst=Martin&rft_id=info%3Adoi%2F10.1128%2Faac.02491-16&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792347299773415431 |
| author | Permala, Jesmin, Tarning, Joel, Nosten, François, White, Nicholas J., Karlsson, Mats O., Bergstrand, Martin |
| author_facet | Permala, Jesmin, Tarning, Joel, Nosten, François, White, Nicholas J., Karlsson, Mats O., Bergstrand, Martin, Permala, Jesmin, Tarning, Joel, Nosten, François, White, Nicholas J., Karlsson, Mats O., Bergstrand, Martin |
| author_sort | permala, jesmin |
| container_issue | 5 |
| container_start_page | 0 |
| container_title | Antimicrobial Agents and Chemotherapy |
| container_volume | 61 |
| description | <jats:title>ABSTRACT</jats:title> <jats:p>Intermittent preventive treatment (IPT) is used to reduce malaria morbidity and mortality, especially in vulnerable groups such as children and pregnant women. IPT with the fixed dose combination of piperaquine (PQ) and dihydroartemisinin (DHA) is being evaluated as a potential mass treatment to control and eliminate artemisinin-resistant falciparum malaria. This study explored alternative DHA-PQ adult dosing regimens compared to the monthly adult dosing regimen currently being studied in clinical trials. A time-to-event model describing the concentration-effect relationship of preventive DHA-PQ administration was used to explore the potential clinical efficacy of once-weekly adult dosing regimens. Loading dose strategies were evaluated and the advantage of weekly dosing regimen was tested against different degrees of adherence. Assuming perfect adherence, three tablets weekly dosing regimen scenarios maintained malaria incidence of 0.2 to 0.3% per year compared to 2.1 to 2.6% for all monthly dosing regimen scenarios and 52% for the placebo. The three tablets weekly dosing regimen was also more forgiving (i.e., less sensitive to poor adherence), resulting in a predicted ∼4% malaria incidence per year compared to ∼8% for dosing regimen of two tablets weekly and ∼10% for monthly regimens (assuming 60% adherence and 35% interindividual variability). These results suggest that weekly dosing of DHA-PQ for malaria chemoprevention would improve treatment outcomes compared to monthly administration by lowering the incidence of malaria infections, reducing safety concerns about high PQ peak plasma concentrations and being more forgiving. In addition, weekly dosing is expected to reduce the selection pressure for PQ resistance.</jats:p> |
| doi_str_mv | 10.1128/aac.02491-16 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin, Chemie und Pharmazie |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTEyOC9hYWMuMDI0OTEtMTY |
| imprint | American Society for Microbiology, 2017 |
| imprint_str_mv | American Society for Microbiology, 2017 |
| institution | DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229 |
| issn | 0066-4804, 1098-6596 |
| issn_str_mv | 0066-4804, 1098-6596 |
| language | English |
| last_indexed | 2024-03-01T17:51:43.56Z |
| match_str | permala2017predictionofimprovedantimalarialchemopreventionwithweeklydosingofdihydroartemisininpiperaquine |
| mega_collection | American Society for Microbiology (CrossRef) |
| physical | |
| publishDate | 2017 |
| publishDateSort | 2017 |
| publisher | American Society for Microbiology |
| record_format | ai |
| recordtype | ai |
| series | Antimicrobial Agents and Chemotherapy |
| source_id | 49 |
| spelling | Permala, Jesmin Tarning, Joel Nosten, François White, Nicholas J. Karlsson, Mats O. Bergstrand, Martin 0066-4804 1098-6596 American Society for Microbiology Infectious Diseases Pharmacology (medical) Pharmacology http://dx.doi.org/10.1128/aac.02491-16 <jats:title>ABSTRACT</jats:title> <jats:p>Intermittent preventive treatment (IPT) is used to reduce malaria morbidity and mortality, especially in vulnerable groups such as children and pregnant women. IPT with the fixed dose combination of piperaquine (PQ) and dihydroartemisinin (DHA) is being evaluated as a potential mass treatment to control and eliminate artemisinin-resistant falciparum malaria. This study explored alternative DHA-PQ adult dosing regimens compared to the monthly adult dosing regimen currently being studied in clinical trials. A time-to-event model describing the concentration-effect relationship of preventive DHA-PQ administration was used to explore the potential clinical efficacy of once-weekly adult dosing regimens. Loading dose strategies were evaluated and the advantage of weekly dosing regimen was tested against different degrees of adherence. Assuming perfect adherence, three tablets weekly dosing regimen scenarios maintained malaria incidence of 0.2 to 0.3% per year compared to 2.1 to 2.6% for all monthly dosing regimen scenarios and 52% for the placebo. The three tablets weekly dosing regimen was also more forgiving (i.e., less sensitive to poor adherence), resulting in a predicted ∼4% malaria incidence per year compared to ∼8% for dosing regimen of two tablets weekly and ∼10% for monthly regimens (assuming 60% adherence and 35% interindividual variability). These results suggest that weekly dosing of DHA-PQ for malaria chemoprevention would improve treatment outcomes compared to monthly administration by lowering the incidence of malaria infections, reducing safety concerns about high PQ peak plasma concentrations and being more forgiving. In addition, weekly dosing is expected to reduce the selection pressure for PQ resistance.</jats:p> Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine Antimicrobial Agents and Chemotherapy |
| spellingShingle | Permala, Jesmin, Tarning, Joel, Nosten, François, White, Nicholas J., Karlsson, Mats O., Bergstrand, Martin, Antimicrobial Agents and Chemotherapy, Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine, Infectious Diseases, Pharmacology (medical), Pharmacology |
| title | Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine |
| title_full | Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine |
| title_fullStr | Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine |
| title_full_unstemmed | Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine |
| title_short | Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine |
| title_sort | prediction of improved antimalarial chemoprevention with weekly dosing of dihydroartemisinin-piperaquine |
| title_unstemmed | Prediction of Improved Antimalarial Chemoprevention with Weekly Dosing of Dihydroartemisinin-Piperaquine |
| topic | Infectious Diseases, Pharmacology (medical), Pharmacology |
| url | http://dx.doi.org/10.1128/aac.02491-16 |